Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96H72

UPID:
S39AD_HUMAN

ALTERNATIVE NAMES:
LIV-1 subfamily of ZIP zinc transporter 9; Solute carrier family 39 member 13; Zrt- and Irt-like protein 13

ALTERNATIVE UPACC:
Q96H72; D3DQR6; D3DQR7; E9PLY1; E9PQV3; Q659D9; Q8N7C9; Q8WV10

BACKGROUND:
The Zinc transporter ZIP13, or Zrt- and Irt-like protein 13, functions as a zinc transporter, crucial for zinc homeostasis in the cytosol. Its role extends to influencing beige adipocyte differentiation, suggesting a broader impact on cellular metabolism and energy regulation.

THERAPEUTIC SIGNIFICANCE:
Given its link to Ehlers-Danlos syndrome, spondylodysplastic type, 3, ZIP13 represents a significant target for research into connective tissue disorders. The disease's manifestations, including skeletal abnormalities and tissue fragility, highlight the therapeutic potential of targeting ZIP13. Understanding the role of Zinc transporter ZIP13 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.